Olema Pharmaceuticals just closed enrollment in OPERA-01, the first registrational test of palazestrant as a once-daily oral complete estrogen-receptor antagonist in second- and third-line metastatic breast cancer. Completing the study removes the last recruitment variable that had hung over the calendar. Management now points to a first-quarter readout next year rather than the fall window it had been advertising. That slip is not a protocol failure so much as a reminder that event-driven oncology studies wait on progression events, not press calendars. The equity already trades as a cash-backed option on that single controlled experiment.
The balance sheet still funds the wait. Cash and marketable securities stood near $461 million at mid-year, after a late-year follow-on that rebuilt the treasury. Half-year operating spend is already running well above last year as two late-stage programs and a KAT6 inhibitor move in parallel. General and administrative cost more than doubled as the company hires for a possible first commercial launch. Spending like an integrated oncology company before the first approval is the honest read of the quarter, and it is also the item that shortens runway if the readout disappoints.
The investment debate is whether palazestrant can show progression-free survival benefit in both ESR1-mutant and wild-type patients, the claim that would separate it from elacestrant, which is already on the label for the mutant subset. A second, earlier asset, OP-3136, posted first-in-human activity at ASCO and now has a Bayer-supplied combination study in prostate cancer. Neither of those options resolves the next several months. The question the first half of next year answers is whether the oral endocrine thesis survives contact with a controlled, event-driven Phase 3.